US 12,383,607 B2
Topical composition for improved healing of open wounds
Mona E. Buice, Nicholson, GA (US); David M. Sailors, Athens, GA (US); and Joshua Z Greeson, Brooklet, GA (US)
Assigned to Eleos Pharmaceuticals, Inc., Watkinsville, GA (US)
Filed by Eleos Pharmaceuticals, Inc., Watkinsville, GA (US)
Filed on Aug. 28, 2024, as Appl. No. 18/818,363.
Application 18/818,363 is a continuation of application No. 18/056,981, filed on Nov. 18, 2022, abandoned.
Application 18/056,981 is a continuation of application No. 16/165,502, filed on Oct. 19, 2018, abandoned.
Claims priority of provisional application 62/678,574, filed on May 31, 2018.
Claims priority of provisional application 62/574,481, filed on Oct. 19, 2017.
Prior Publication US 2025/0025534 A1, Jan. 23, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/80 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/196 (2006.01); A61K 31/197 (2006.01); A61K 38/28 (2006.01); A61K 38/57 (2006.01); A61K 47/36 (2006.01); A61P 17/02 (2006.01); A61P 31/04 (2006.01); A61P 41/00 (2006.01); A61P 3/10 (2006.01)
CPC A61K 38/28 (2013.01) [A61K 9/0014 (2013.01); A61K 9/006 (2013.01); A61K 9/06 (2013.01); A61K 47/36 (2013.01); A61P 17/02 (2018.01); A61P 3/10 (2018.01)] 26 Claims
OG exemplary drawing
 
1. A method of treating a diabetic foot ulcer in a human patient in need thereof, wherein the diabetic foot ulcer is refractory to systemic insulin the method comprising:
(a) determining that the patient has a glucose level of greater than 200 mg/dL at the site of the diabetic foot ulcer that is greater than the patient's systemic blood glucose level; and
(b) administering to the patient a pharmaceutical composition comprising insulin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is topically administered to the patient at the site of the diabetic foot ulcer.